The company was awarded the title of municipal innovative small and medium-sized enterprise, and AI provides one-stop service for innovative drugs.

Recently, Shanghai Space Peptides Co., Ltd. (Space Peptides), as a one-stop service company for innovative drugs introduced by Zhichuang TOP, was rated as an innovative small and medium-sized enterprise in Shanghai in 2023. Shenpu Zetai focuses on the research and development of innovative peptide drugs, focusing on innovative, hard-to-find drugs and forward-looking targets. They use Chemical Space drug design and screening as their core technology, and combine it with artificial intelligence and drug structure big data to provide end-to-end services from peptide innovative drug discovery to CDMO

The process of new drug discovery has high cost, long cycle and high failure rate, but it is an important and critical step in drug research and development. Senpu Zetai uses digital technology to build a database called chemical space, which has strong logical connections and can provide fast, accurate and visual advantages in new drug discovery

Based on large amounts of data and new drug generation algorithms, Chemical Space helps researchers quickly screen out drug molecules with desired pharmacodynamic effects and minimal side effects, and quickly discover target new compounds or compound groups. Chemical Space also uses artificial intelligence-driven drug generation fingerprint libraries to visually display them to drug design chemists to promote the design, screening, synthesis and verification of drug molecules, realize data iteration, and make new drug design more accurate and intelligent

Currently, Senpu Zetai delivers new patented molecules (PCT) to global customers and has achieved breakthroughs in key R&D nodes - the delivery confirmation time of preclinical candidate compounds (PCC) has been shortened from 4-6 years to 6-12 In recent months, R&D costs have been reduced by more than 50%-70%, and the speed and efficiency have been significantly improved.

▲Shengpu Zetai peptide AI drug design and screening process is accurate and fast, and can reduce R&D costs and R&D cycles at the same time. It has successfully applied for PCT patents for global new drug compounds and delivered them to many domestic and foreign countries

At present, the company's main business covers new drug discovery to industrial production, and it has reached cooperation with domestic and foreign pharmaceutical companies such as Roche of Switzerland, Hubei Renfu Pharmaceutical, and Jiangsu Kangyuan Pharmaceutical. The peptide fusion inhibitor against COVID-19 infection developed by the company in cooperation with Xiamen University was awarded the leading technology in the biomedical field on the 2020 "Science and Technology China" list. The company has built a Shanghai headquarters, a drug design and screening center in Basel, Switzerland, a chemical synthesis center in Zhangzhou, Fujian, a preclinical verification center in Xiamen, and a CDMO center for API production in Taizhou, Jiangsu, to provide one-stop services for innovative drugs.

The content that needs to be rewritten is: ▲Some of Shengpu Zetai’s cooperative customers

Under the guidance of the "Digital Putuo" industrial digitalization policy, the company is on the track of rapid development and has become an emerging force in the field of interdisciplinary cutting-edge innovation. In the full-cycle corporate services of Zhichuang TOP's development of "Wonderful Life" 4 X key industries, the company is booming

Reinterpretation Reinterpretation is the rewriting of content in a way that does not change the original meaning. The content needs to be rewritten into Chinese, and the original sentence does not need to appear

CDMO: The full name is Contract Development and Manufacturing Organization. It is a medical and health service model that aims to provide pharmaceutical companies with a full range of R&D, production and sales services.

CRO: The full name is Contract Research Organization (commissioned research organization). It is an organization commissioned by pharmaceutical companies or biotechnology companies to provide research services. It provides non-clinical and clinical trials, data analysis, and regulatory consultation required for the development of new drugs. and other professional services.

Source: Shanghai Putuo

The above is the detailed content of The company was awarded the title of municipal innovative small and medium-sized enterprise, and AI provides one-stop service for innovative drugs.. For more information, please follow other related articles on the PHP Chinese website!